Email this article 
Lavomax - new potential of the complex therapy of genital herpes
- Authors: Udzhukhu VY.1, Kubylinskiy AA1, Udzhukhu VY.1, Kubylinsky AA1
-
Affiliations:
- Issue: Vol 87, No 4 (2011)
- Pages: 108-110
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.08.2011
- URL: https://vestnikdv.ru/jour/article/view/1059
- DOI: https://doi.org/10.25208/vdv1059
- ID: 1059
Cite item
Full Text
Abstract
The goal of this study was to assess clinical efficacy and safety of Lavomax and to provide pathogenetic grounds for its
use in the complex therapy of patients suffering from genital herpes. The study subjects were 64 patients suffering from
genital herpes.
Their diagnosis was verified on the basis of ELISA and PCR results. Immunoassays revealed various disorders of immune
homeostasis and natural resistance. These results confirm that there are pathogenetic grounds to use Lavomax in the
complex therapy of genital herpes. Complex treatment with the use of Lavomax normalizes immune homeostasis and
quickly reduces clinical manifestations of herpes significantly reducing the frequency and duration of recurrences of the
disease.
use in the complex therapy of patients suffering from genital herpes. The study subjects were 64 patients suffering from
genital herpes.
Their diagnosis was verified on the basis of ELISA and PCR results. Immunoassays revealed various disorders of immune
homeostasis and natural resistance. These results confirm that there are pathogenetic grounds to use Lavomax in the
complex therapy of genital herpes. Complex treatment with the use of Lavomax normalizes immune homeostasis and
quickly reduces clinical manifestations of herpes significantly reducing the frequency and duration of recurrences of the
disease.
Keywords
About the authors
V Yu Udzhukhu
Email: sovet140011@mail.ru
A A Kubylinskiy
V Yu Udzhukhu
A A Kubylinsky
References
- Адаскевич В.П. Инфекции, передаваемые половым путем. Руководство для врачей. Н. Новгород: Медицинская книга. Издательство Нижегородской государственной медицинской академии 2004.
- Armstrong G.L., Schillmger J., Markowitz L., et all. Incidence of herpes simplex virus type 2 infection in the United States. Air. J Epidemiol 2001; 153: 912-920.
- Hollier L.M., Straub H. Genital herpes. Clin Evid (Online) 2011; pii: 1603.
- Иванов О.Л., Молочков В.А., Бутов Ю.С. Кожные и венерические болезни. М.: Шико 2002.
- Grossman J.H. Herpes simplex virus (HSV infection). Clin Obstet Gyn 2002; 25: (3): 552-562.
- Семенова Т.Б. Генитальный герпес у женщин. РМЖ 2001; 9: (6): 237-242.
- Mertz G.J. Epidemiology of genital herpes infections. Infect Dis Clin North Am 2003; (7): 825-839.
- Буданов П.В. Проблемы терапии рецидивирующего генитального герпеса. Вопр. гинекол., акуш. и перинатол. 2004; 3: (4): 94-98.
- Короткий Н.Г. Современная наружная терапия дерматозов (с элементами физиотерапии). Тверь: Губернская медицина 2001.
- Flotte T.R., Trapnell B.C., Humphries M., et all. Phase 2 Clinical Trial of a Recombinant Adenoassociated Virus Vector Expressing Alpha 1 Antitrypsin: Interim Results. Hum Gene Ther 2011.
- Field H.J., Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist Updat 2011; 14: (1): 45-51.
- Sauerbrei A., Deinhardt S., Zell R. et all. Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010; 1: (6): 55-57.
- Randolph A.G., Hartshorn R.M., Washington A.E. Acyclovir prohylaxis in late pregnancy to prevent neonatal herpes: a cost effectiveness analysis. Obstetrics and Gynecology 2006, 88; (4/1): 603-610.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).